September 10, 2024 07:07 AM EDTUpdated 07:55 AM

Centessa to take narcolepsy drug into Phase 2 after no sign of side effects that doomed earlier competitor

Drew Armstrong

Executive Editor

Centessa Pharmaceuticals plans to take its orexin receptor 2 agonist into mid-stage testing for narcolepsy after a Phase 1 study showed signs of efficacy. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Centessa to take narcolepsy drug into Phase 2 after no sign of side effects that doomed earlier competitor

Drew Armstrong

Executive Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Merck's Eliav Barr on subcutaneous Keytruda, Summit and deal shopping

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

BioNTech rolls out Phase 2 lung cancer data as VEGF bispecifics take center stage

Roche outlines commercial manufacturing strategy for GLP-1/GIP assets

Boehringer plans NDA filing for pulmonary fibrosis drug following Phase 3 data

Breaking down silos with a new quantitative approach to drug development

Centes­sa to take nar­colep­sy drug in­to Phase 2 af­ter no sign of side ef­fects that doomed ear­li­er com­peti­tor

Executive Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Centessa to take narcolepsy drug into Phase 2 after no sign of side effects that doomed earlier competitor